Overview

• A global meta-analysis of 11 randomized trials found participants regained significant weight beginning around eight weeks after stopping drugs such as Ozempic, Wegovy and Mounjaro.
• The review combined data from 1,574 treated patients and 893 controls across Orlistat, Naltrexone/Bupropion, Phentermine/Topiramate and GLP-1 receptor agonists.
• Patients with the greatest initial weight loss experienced larger rebounds, even after joining lifestyle modification programs.
• U.S. figures show two-thirds of self-paying patients discontinue GLP-1 therapies within a year, while monthly treatment costs reach several hundred euros.
• Diabetologists including Stephan Martin argue obesity must be managed as a chronic condition with long-term pharmacotherapy to maintain weight control.